Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
GNbAC1 placebo
BIOLOGICAL
3 trials
Sponsors
GeNeuro Innovation SAS
, GeNeuro Australia PTY Ltd
Conditions
Multiple Sclerosis
Phase 1
First-in-Human Study With GNbAC1 in Healthy Volunteers
Completed
NCT01699555
GeNeuro Innovation SAS
Multiple Sclerosis
Start: 2011-07-31
End: 2012-08-31
Updated: 2020-10-20
Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers
Completed
NCT03574428
GeNeuro Australia PTY Ltd
Multiple Sclerosis
Start: 2018-05-08
End: 2018-11-02
Updated: 2020-10-20
Phase 2
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Completed
NCT01639300
GeNeuro Innovation SAS
Multiple Sclerosis
Start: 2012-07-31
End: 2014-04-30
Updated: 2021-02-08
Related Papers
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env.
2019-07-13
9 citations
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
2012-11-29
51 citations